Chimeric antigen receptor T_reg therapy in transplantation

Area of Science:

• Immunology and Transplantation Science
• Cellular Therapy
• Biotechnology

Background:

• Current organ transplantation therapies face challenges with efficacy and side effects of conventional immunosuppressants.
• Polyclonal regulatory T cells (Tregs) offer potential but have limitations that hinder widespread clinical application.
• Chimeric antigen receptor (CAR) technology presents an opportunity to engineer T cells for enhanced therapeutic functions.

Purpose of the Study:

• To review the potential of CAR T regulatory cell (Treg) therapies in advancing organ transplantation.
• To analyze how CAR T_reg therapy can address drawbacks associated with polyclonal T_regs and conventional immunosuppressants.
• To explore current preclinical findings, design considerations, and therapeutic targets for CAR T_reg applications in transplantation.

Main Methods:

• Comprehensive review of existing preclinical data on CAR T_reg therapy in transplantation models.
• Analysis of CAR T_reg design strategies and identification of relevant targets.
• Exploration of current challenges and future research directions for CAR T_reg efficacy.

Main Results:

• Preclinical findings suggest CAR T_reg therapy holds promise for modulating alloimmune responses in transplantation.
• CAR T_reg design offers specificity and potential for improved Treg function compared to polyclonal counterparts.
• Various targets are being explored for CAR T_reg engagement in the transplant microenvironment.

Conclusions:

• CAR T_reg therapy represents a promising frontier in organ transplantation, potentially reducing reliance on chemical immunosuppressants.
• Further studies and clinical trials are essential to fully elucidate the efficacy and scope of CAR T_reg applications.
• Overcoming current impediments is crucial for translating CAR T_reg potential into clinical success.